Ravulizumab-Cwvz

Introduction Overview

Generic Name

ravulizumab-cwvz

Brand Name

Ultomiris

Dosage Form

intravenous injection (10 mg/mL, 100 mg/mL)

Drug Class

Selective immunosuppressants

Pharmacokinetics

Absorption:
Ravulizumab is administered exclusively via intravenous infusion, thereby ensuring complete systemic bioavailability. Upon infusion, as a monoclonal antibody, it exhibits immediate presence in the systemic circulation, bypassing gastrointestinal absorption mechanisms common to oral drugs. The pharmacokinetic profile is influenced predominantly by distribution and elimination rather than absorption variables.

Distribution:
Following IV administration, ravulizumab demonstrates a volume of distribution approximating the plasma volume consistent with monoclonal antibodies, typically in the range of 3–5 liters. It circulates primarily in the plasma compartment, binding to the complement protein C5. Ravulizumab does not readily cross cellular membranes due to its large molecular size, and tissue penetration is limited but sufficient to inhibit complement activity. The extent of distribution can be influenced by patient factors including body weight and disease state, which impact dosing regimens.

Metabolism:
Ravulizumab is metabolized via proteolytic catabolism predominantly in the reticuloendothelial system, similar to endogenous IgG antibodies. It undergoes degradation to small peptides and amino acids through non-specific proteolytic pathways rather than hepatic cytochrome P450 enzymes. This catabolic mechanism reduces susceptibility to hepatic drug-drug interactions common in metabolized small-molecule drugs and contributes to a relatively stable clearance across populations.

Elimination:
Elimination of ravulizumab occurs via proteolytic degradation eliminating intact antibody molecules from plasma. Its half-life ranges approximately 50 to 60 days, significantly longer than its predecessor eculizumab due to engineered modifications enhancing FcRn receptor affinity and recycling. This extended half-life facilitates maintenance doses every 4 to 8 weeks depending on patient weight and condition treated. Clearance is impacted by body weight, complement protein binding saturation, and disease state, with dosing adjustments ensuring adequate target saturation for complement inhibition. Elimination pathways do not involve renal or hepatic excretion, consistent with monoclonal antibody pharmacokinetics.

Dosage Forms

Available Dosage Forms:
Ravulizumab is supplied as an intravenous (IV) injection available in the following formulations:
- 10 mg/mL concentration in single-dose vials (300 mg/30 mL)
- 100 mg/mL concentration in single-dose vials (300 mg/3 mL and 1,100 mg/11 mL)
- Single-dose cartridge containing 245 mg/3.5 mL (70 mg/mL)

Dosages for Adults and Adolescents:
Dosing of ravulizumab is weight-based and varies between loading and maintenance phases. Generally, for adults and adolescents:
- Loading doses are administered initially, with two infusions two weeks apart to achieve therapeutic levels.
- Maintenance doses are administered every 4 to 8 weeks depending on weight range.
- Patients weighing 20 kg to <100 kg: maintenance dosing every 8 weeks
- Patients weighing 5 kg to <20 kg: maintenance dosing every 4 weeks
Doses are adjusted precisely based on detailed weight brackets to ensure effective complement blockade.

Specific Patient Populations:
- Pediatric patients (1 month and older) are approved for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) with careful weight-based dosing.
- For generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), only adult patients are currently approved for treatment.
- Patients transitioning from eculizumab require a washout period of approximately two weeks prior to initiating ravulizumab to prevent overlapping immunosuppression.
- Subcutaneous administration of ravulizumab has not been evaluated or approved; only intravenous route is authorized.
- Dose modifications may be necessary in patients undergoing plasma exchange or receiving intravenous immunoglobulins due to altered clearance.
Clinicians should follow precise dosing schedules and monitor weight changes to adjust dosing accordingly. Detailed dosing tables provided in the package insert should guide therapy initiation and maintenance.

Mechanism Of Action

Ravulizumab-cwvz is a humanized monoclonal antibody engineered to selectively bind to the complement component protein C5, a critical effector in the terminal complement cascade. By specifically binding to C5, ravulizumab prevents its cleavage into C5a and C5b, which inhibits subsequent formation of the membrane attack complex (C5b-9) and blocks complement-mediated cell lysis. This targeted inhibition prevents the detrimental immune-mediated destruction of host cells, a pathogenic mechanism underlying diseases such as paroxysmal nocturnal hemoglobinuria and myasthenia gravis.

At the molecular level, ravulizumab binds with high affinity to a distinct epitope on the C5 protein, stabilizing it in an inactive conformation. This blockade prevents activation of the terminal complement pathway, thereby reducing inflammatory processes and the cascade leading to cell membrane damage. The prevention of C5b-9 deposition is pivotal in protecting blood cells and neuromuscular junctions from immune attack. Ravulizumab’s binding affinity and extended serum half-life are enhanced by engineered Fc modifications that improve recycling via neonatal Fc receptor (FcRn)-mediated pathways.

On a cellular pathway level, the inhibition of C5 cleavage translates into decreased recruitment and activation of inflammatory cells mediated by C5a, a potent anaphylatoxin involved in chemotaxis and activation of immune responses. This dual blockade both reduces direct cellular damage and modulates inflammatory signaling, decreasing tissue injury and ameliorating clinical symptoms in complement-driven diseases.

Clinically, ravulizumab’s mechanism provides long-lasting targeted immunosuppression without broad immune cell depletion, thereby improving muscle strength and neurologic function in myasthenia gravis patients and preventing hemolytic damage in PNH. Comparative to earlier drugs such as eculizumab, ravulizumab has modifications that prolong duration of complement inhibition, allowing for less frequent dosing and potentially improving patient compliance. Clinical studies have demonstrated ravulizumab’s efficacy in reducing disease burden by persistent complement blockade. Ongoing research explores its utility in other complement-mediated disorders as well.

Pharmacological Actions

Selective inhibition of complement component C5, preventing its cleavage into pro-inflammatory fragments C5a and C5b.
Blockade of the terminal complement cascade to inhibit formation of the membrane attack complex (C5b-9), reducing cell lysis.
Suppression of complement-mediated immune response implicated in autoimmune and hematologic disorders.
Reduction of complement-mediated inflammation and tissue damage.
Immunomodulatory effects without broadly suppressing lymphocyte populations.
Prolonged complement inhibition due to engineered Fc region enhancing antibody half-life.
Decreased recruitment and activation of inflammatory cells via inhibition of C5a anaphylatoxin.
Improvement of neuromuscular transmission by protecting the neuromuscular junction from complement attack in myasthenia gravis.
Prevention of hemolysis and thrombosis by protecting erythrocytes in paroxysmal nocturnal hemoglobinuria.
Inhibition of complement-mediated thrombotic microangiopathy in atypical hemolytic uremic syndrome.
Reduction of autoimmune-mediated damage in neuromyelitis optica spectrum disorder.
Minimized immunogenicity due to humanized monoclonal antibody structure.
Synergistic benefit when used in complement-driven diseases refractory to conventional immunosuppression.
FcRn-mediated recycling confers sustained serum levels and extended dosing intervals.
Potential for combination therapy with complement-modulating agents in complex immune disorders.

Therapeutic Or Clinical Uses

Treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
Management of paroxysmal nocturnal hemoglobinuria for adults and pediatric patients aged 1 month and older.
Treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy in adults and children aged 1 month and older.
Treatment of neuromyelitis optica spectrum disorder in adults seropositive for anti-aquaporin-4 antibodies.
Prevention of complement-mediated red blood cell destruction and hemolysis.
Reduction in the occurrence of thrombosis and hemolytic events associated with complement activation.
Improvement in muscle strength and daily functioning in myasthenia gravis patients.
Inhibition of complement activation to prevent disease progression in complement-driven autoimmune diseases.
Use as a long-acting complement inhibitor allowing extended dosing intervals to enhance adherence.
Treatment option for patients intolerant or refractory to eculizumab therapy.
Complement blockade in disorders characterized by uncontrolled terminal complement activation.
Demonstrated efficacy in clinical trials improving quality of life and reducing exacerbations in target diseases.
Reduction of hospitalization rates and disease morbidity associated with complement-mediated conditions.
Used as part of comprehensive management in hematologic and neurologic autoimmune diseases.
Indicated in both adult and pediatric populations where specified, with weight-adjusted dosing.

Side Or Adverse Effects

Diarrhea occurring in approximately 15% of patients treated for generalized myasthenia gravis.
Hypertension or elevated blood pressure reported in 14% of treated patients.
Stomach pain or abdominal discomfort observed in about 6% of patients.
Upper respiratory tract infections occurring in 14% of generalized myasthenia gravis patients.
Urinary tract infections reported in approximately 6% of cases.
Back pain experienced by roughly 8% of treated individuals.
Dizziness presenting in about 9% of patients undergoing therapy.
Potential for serious allergic reactions including anaphylaxis; symptoms include hives, swelling, and respiratory distress.
Risk of serious infections due to immune system modulation, particularly meningococcal infections.
Possible symptoms of infection include fever, rash, headache, muscle aches, confusion, photophobia, and stiff neck.
Increased susceptibility to gonorrhea infection, a sexually transmitted disease.
Injection-related reactions such as light-headedness, chest pain, and localized swelling.
Potential for new or worsening symptoms upon treatment discontinuation, including fatigue, confusion, and seizures.
Rare reports of infusion-related adverse events necessitating monitoring during and post-infusion.
Other less common side effects include nausea, vomiting, and flu-like symptoms.

Precautions

Administer meningococcal vaccination at least two weeks prior to initiating therapy, when possible, due to risk of meningococcal infections.
Enroll patients in the Ultomiris REMS program to ensure informed consent and monitoring for serious infection risks.
Monitor patients closely for signs and symptoms of infection throughout treatment duration and for at least 8 months after discontinuation.
Avoid initiation in patients with unresolved serious Neisseria meningitidis infection.
Provide prophylactic antibiotics if treatment must begin prior to completion of vaccination schedules.
Advise patients on recognizing early infection symptoms and guide them to seek prompt medical attention if these occur.
Consider pregnancy status; discuss potential risks and benefits as definitive safety profile during pregnancy is lacking.
Avoid breastfeeding during treatment and for 8 months following the last dose due to unknown excretion in human milk.
Exercise caution in patients with a history of severe allergic reactions to monoclonal antibodies.
Regularly evaluate patients for immune system status and concomitant infections, especially if immunocompromised.
Adjust dosing based on body weight and monitor for changes during therapy course.
Ensure vaccination for pediatric patients against pneumonia and influenza type B (Hib) when treating approved conditions.
Advise safe sexual practices given increased risk of gonorrhea and other infections.
Observe patients carefully during infusion for infusion-related reactions and have emergency interventions ready.
Educate patients on the importance of adherence to dosing schedules and follow-up appointments.

Warnings

Ravulizumab suppresses terminal complement activity, increasing susceptibility to serious and potentially fatal infections, notably meningococcal disease.
Patients may develop life-threatening meningitis despite vaccination; vaccination does not fully eliminate infection risk.
Carry the Patient Safety Card at all times during therapy and for at least 8 months after the last dose, highlighting infection risk signs.
Discontinue or delay treatment if active serious infection is present prior to therapy initiation.
Monitor for signs of infection including fever, rash, headache, neck stiffness, photophobia, and flu-like symptoms; seek immediate medical care if present.
An increased risk of gonorrhea infection exists; counsel patients on preventive measures and monitor for symptoms.
Avoid use in pediatric populations outside approved indications due to lack of safety and efficacy data.
Patients with unresolved Neisseria meningitidis infection should not receive ravulizumab.
Immunosuppression may mask signs of infection; maintain high clinical suspicion.
Discontinuation can result in recurrence of disease symptoms and requires careful monitoring.
Potential hypersensitivity or infusion reactions require monitoring during and post-infusion.
Pregnancy safety has not been established; use only if potential benefit justifies risk to fetus.
Impaired ability to respond to vaccinations due to complement blockade.
Extreme caution in concomitant use with immunosuppressants or other biological therapies.
Ensure comprehensive patient education on signs of infection and adherence to monitoring requirements.

Contraindication

Known hypersensitivity or allergic reaction to ravulizumab or any component of its formulation.
Patients with an active, unresolved meningococcal infection or systemic Neisseria meningitidis infection.
Patients not vaccinated against meningococcal disease when the risks of delaying treatment are outweighed by the urgency of therapy initiation unless prophylactic antibiotics are administered.
Use in patients with unresolved serious infections until infections are adequately treated.
Contraindicated for subcutaneous use due to lack of evaluated safety and efficacy.
Not approved for pediatric use in generalized myasthenia gravis or neuromyelitis optica spectrum disorder.
Concomitant administration with agents known to interfere with complement function without appropriate monitoring.
Patients with known active systemic bacterial infections besides meningococcal infections without appropriate management.
Known severe infusion reaction history to monoclonal antibody therapies without appropriate desensitization protocols.
Contraindications related to hypersensitivity to excipients like polysorbate 80 in formulation.
Not to be used as sole therapy for Shiga toxin-producing Escherichia coli-related HUS.
Patients previously demonstrating severe intolerance or adverse events attributable to complement inhibitors prohibiting continued use.
Use in patients with pre-existing neurological conditions without established clinical benefit-risk assessment.

Drug Interactions

Potentially reduced efficacy when co-administered with intravenous immunoglobulins or plasma exchange therapies; supplemental dosing may be required.
Monitor patients closely when using neonatal Fc receptor (FcRn) blockers such as efgartigimod or rozanolixizumab, which may impact ravulizumab pharmacodynamics.
No significant interaction with cytochrome P450-metabolized drugs due to non-hepatic proteolytic metabolism.
No known major pharmacokinetic interactions with commonly used medications due to monoclonal antibody elimination pathways.
Concurrent immunosuppressive agents may increase infection risk; use with caution and under medical supervision.
No interaction expected with vaccines, though efficacy of live vaccines may be affected; vaccination timing must be managed appropriately.
Potential additive immunosuppressive effects when combined with other biologics targeting immune pathways.
Antibiotic prophylaxis may be necessary when initiating therapy prior to completion of meningococcal vaccination.
No data supporting interaction with hormonal contraceptives, but pregnancy planning should consider immunosuppression effects.
Drug interactions with agents that modify complement activity require careful clinical monitoring for therapeutic effectiveness.
Dose adjustments or supplemental dosing after plasma exchange, plasmapheresis, or immunoadsorption procedures to maintain efficacy.
No clinically meaningful interactions with dietary supplements have been reported, but patients should inform providers of all substances used.
Use caution when transitioning from eculizumab to ravulizumab due to overlapping complement blockade and possible cumulative immunosuppression.
Concomitant medications requiring immune competence for efficacy should be assessed on a case-by-case basis.
Monitoring for infections is essential given additive risks when combined with other immunomodulatory drugs.

Preparations Of The Drug

Ultomiris (ravulizumab-cwvz) injection formulation available in several single-dose vial strengths: 10 mg/mL and 100 mg/mL concentrations.
Available in single-dose cartridges and vials for intravenous infusion with specific concentration and volume such as 245 mg/3.5 mL cartridge (70 mg/mL), 300 mg/3 mL vial (100 mg/mL), and 1,100 mg/11 mL vial (100 mg/mL).
Formulated with inactive ingredients including polysorbate 80 (vegetable origin), sodium phosphate dibasic and monobasic, sodium chloride (in 10 mg/mL formulation), L-arginine (in 100 mg/mL formulation), sucrose, and Water for Injection.
Stored refrigerated between 2°C to 8°C (36°F to 46°F), protected from light in original carton; do not freeze or shake.
Diluted infusion solutions must be stored at 2°C to 8°C and used within 24 hours including infusion time to maintain stability.
Provided as a sterile, preservative-free liquid intended for intravenous use only by healthcare providers.
The product is supplied by Alexion Pharmaceuticals, Inc., ensuring high manufacturing standards and quality control.
Not intended for subcutaneous administration; only for intravenous infusions with dosing individualized by body weight and indication.
Detailed administration instructions include infusion rates varying from 0.4 to 1.4 hours tailored to patient weight and clinical condition.
Packaging labeled for single use to prevent contamination and ensure dose accuracy.
Each vial or cartridge comes with a Patient Safety Card to inform patients of infection risks and management.
Available only through authorized distribution channels adhering to the Ultomiris REMS program to mitigate infection risk.
The formulation’s excipients and buffer components are selected to maintain protein stability and minimize immunogenicity.
Handling protocols emphasize gentle preparation techniques to preserve protein integrity during dilution and administration.
Batch consistency and lot traceability are maintained to comply with regulatory standards for biological products.